Academic Journal
Impact of HER2 on prognosis and benefit from adjuvant chemotherapy in stage II/III gastric cancer patients: a multicenter observational study
| العنوان: | Impact of HER2 on prognosis and benefit from adjuvant chemotherapy in stage II/III gastric cancer patients: a multicenter observational study |
|---|---|
| المؤلفون: | Gao, Xianchun, Zhao, Lulu, Zhang, Nannan, Han, Weili, Liu, Kun, Yan, Junya, Chen, Ling, Pan, Yan, Li, Renlong, Li, Wenjiao, Zhang, Haohao, Li, Hongwei, Wang, Shibo, Gao, Xiaoliang, Niu, Penghui, Wang, Wanqing, Ji, Gang, Zhao, Qingchuan, Lu, Yuanyuan, Li, Zengshan, Shang, Lei, Liang, Han, Wu, Kaichun, Deng, Jingyu, Chen, Yingtai, Nie, Yongzhan |
| المصدر: | International Journal of Surgery ; volume 109, issue 5, page 1330-1341 ; ISSN 1743-9159 |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health) |
| سنة النشر: | 2023 |
| الوصف: | Background: Human epidermal growth factor receptor 2 (HER2) is a well-developed therapeutic target in breast and gastric cancer (GC). However, the impact of HER2 on survival and benefit from fluorouracil-based adjuvant chemotherapy remains unclear in patients with GC. Materials and Methods: This multicenter cohort study involved 5622 consecutive stage II/III GC patients. HER2 expression was assessed prospectively via immunohistochemistry (IHC). The staining intensity was graded on a scale of 0 to 3+. An IHC score of 2+or 3+was defined as high expression, and a score of 3+was defined as overexpression. Results: HER2 overexpression was independently associated with a lower 5-year overall survival (OS) in stage II [hazard ratio (HR), 2.10; 95% CI: 1.41–3.11], but not in stage III GC (HR, 1.00; 95% CI, 0.82–1.20). Further analysis revealed that stage II patients with high HER2 expression showed a poorer response to chemotherapy than stage II patients with low HER2 expression ( P interaction =0.024). The HRs for 5-year OS were 0.51 (95% CI, 0.38–0.70) for stage II patients with low HER2 expression, 0.58 (95% CI, 0.51–0.66) for stage III patients with low HER2 expression, 1.13 (95% CI, 0.61–2.09) for stage II patients with high HER2 expression, and 0.47 (95% CI, 0.36–0.61) for stage III patients with high HER2 expression. Conclusions: Fluorouracil-based adjuvant chemotherapy is insufficient for stage II GC patients with high HER2 expression, indicating that prospective trials are required to validate alternative HER2-targeted adjuvant therapies in the individuals above. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1097/js9.0000000000000370 |
| DOI: | 10.1097/JS9.0000000000000370 |
| الاتاحة: | http://dx.doi.org/10.1097/js9.0000000000000370 https://journals.lww.com/10.1097/JS9.0000000000000370 |
| Rights: | http://creativecommons.org/licenses/by-nc-sa/4.0/ http://creativecommons.org/licenses/by-nc-sa/4.0/ |
| رقم الانضمام: | edsbas.E9727320 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1097/js9.0000000000000370 |
|---|